about
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BPharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a miceSoy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution.Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.In search of physiologically based distribution volume estimates for macromolecules.Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.Is a decrease of microparticles related to improvement of hemostasis after FVIII injection in hemophilia A patients treated on demand?A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
P2860
Q28078281-083E8BB0-6C9F-44E9-B41F-AA84C96573FEQ30685072-EEFE7BC3-C38E-4AB8-96D1-13FB90FDE713Q33954639-629D145E-F2FF-4812-AAB2-A6D3BAD1CF31Q34283156-6BB210F4-9998-4062-B414-E5F7C30D9AC9Q34779399-E67A3A74-7B0F-434E-8C6A-5DAF786AEA8EQ35498838-A2F4776F-8303-4FD5-8912-A00E2A65CD62Q36044569-839C9867-6A40-43B5-9288-79D807751815Q36480548-9B203B14-FA2E-4CDA-A77B-A694D850D77EQ37057618-59EB67ED-2545-450F-AAF9-BCD3A8B9990BQ37686530-B93897A6-5048-4DD0-89DD-C924C42926CBQ38044821-661841E4-1F0A-4ED2-8870-2D811F498C86Q42220577-308D00B4-166C-4A8F-8859-B4A16457F5CFQ42611760-1449E6BA-5619-48FD-9570-74D89340F1FCQ42635428-ABD78DA7-3295-41CE-B873-0D5AFED3CAD2Q45807873-EDB3409C-21ED-495C-8EB6-2E224A68DA12Q45866906-21170392-17C6-40D5-8B0F-55B26EABA6BCQ45869569-9E05A52F-1DE4-43B8-889F-A7A79F4DDBF3Q45869919-10DA4ACA-A00A-480E-AA06-98B01EF8E473Q45871529-9D45D19D-C9CA-40A7-83D6-B51A4CCE1F53Q45882434-0D1E0CB5-F079-471B-B2C7-1AC36AF68F89Q45887347-D260E4F9-C204-451A-B434-311755E05BF9
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The pharmacokinetics of clotting factor therapy.
@ast
The pharmacokinetics of clotting factor therapy.
@en
type
label
The pharmacokinetics of clotting factor therapy.
@ast
The pharmacokinetics of clotting factor therapy.
@en
prefLabel
The pharmacokinetics of clotting factor therapy.
@ast
The pharmacokinetics of clotting factor therapy.
@en
P2860
P1433
P1476
The pharmacokinetics of clotting factor therapy.
@en
P2093
Berntorp E
Björkman S
P2860
P304
P356
10.1046/J.1365-2516.2003.00762.X
P577
2003-07-01T00:00:00Z